These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27643535)

  • 1. Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia.
    Uyen TN; Sakashita K; Al-Kzayer LF; Nakazawa Y; Kurata T; Koike K
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27643535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation.
    Thanh Nha Uyen L; Amano Y; Al-Kzayer LFY; Kubota N; Kobayashi J; Nakazawa Y; Koike K; Sakashita K
    Int J Hematol; 2020 Mar; 111(3):451-462. PubMed ID: 31865541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
    Lin YL; Gui SL; Guo H; Ma JG; Li WP
    Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
    Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
    J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.
    Wang XB; Lin YL; Li ZG; Ma JH; Li J; Ma JG
    J Int Med Res; 2014 Apr; 42(2):292-9. PubMed ID: 24567353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
    Lin YL; Xie PG; Wang L; Ma JG
    Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCDH17 gene promoter demethylation and cell cycle arrest by genistein in gastric cancer.
    Yang Y; Liu J; Li X; Li JC
    Histol Histopathol; 2012 Feb; 27(2):217-24. PubMed ID: 22207556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.
    Lin YL; Wang YP; Li HZ; Zhang X
    Med Sci Monit; 2017 Jul; 23():3318-3323. PubMed ID: 28688232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
    Lin YL; Li YL; Ma JG
    Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.
    Widschwendter A; Ivarsson L; Blassnig A; Müller HM; Fiegl H; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
    Int J Cancer; 2004 Mar; 109(2):163-6. PubMed ID: 14750164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
    Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation.
    Byzia E; Soloch N; Bodnar M; Szaumkessel M; Kiwerska K; Kostrzewska-Poczekaj M; Jarmuz-Szymczak M; Szylberg L; Wierzbicka M; Bartochowska A; Kalinowicz E; Grenman R; Szyfter K; Marszalek A; Giefing M
    Mol Carcinog; 2018 Jul; 57(7):878-885. PubMed ID: 29566279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia.
    Roman-Gomez J; Jimenez-Velasco A; Cordeu L; Vilas-Zornoza A; San Jose-Eneriz E; Garate L; Castillejo JA; Martin V; Prosper F; Heiniger A; Torres A; Agirre X
    Eur J Cancer; 2007 Dec; 43(18):2736-46. PubMed ID: 18032022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia.
    Abdullah M; Choo CW; Alias H; Abdul Rahman EJ; Mohd Ibrahim H; Jamal R; Hussin NH
    Hematology; 2017 Aug; 22(7):386-391. PubMed ID: 28292214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
    Agrawal S; Unterberg M; Koschmieder S; zur Stadt U; Brunnberg U; Verbeek W; Büchner T; Berdel WE; Serve H; Müller-Tidow C
    Cancer Res; 2007 Feb; 67(3):1370-7. PubMed ID: 17283175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
    Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
    Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant methylation of PCDH17 gene in high-grade serous ovarian carcinoma.
    Baranova I; Kovarikova H; Laco J; Dvorak O; Sedlakova I; Palicka V; Chmelarova M
    Cancer Biomark; 2018; 23(1):125-133. PubMed ID: 29991130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.